These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 34523245)

  • 1. Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
    Sagahón-Azúa J; Medellín-Garibay SE; Chávez-Castillo CE; González-Salinas CG; Milán-Segovia RDC; Romano-Moreno S
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00864. PubMed ID: 34523245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.
    LLerena A; Dorado P; Berecz R; González AP; Peñas-LLedó EM
    Eur J Clin Pharmacol; 2004 Feb; 59(12):869-73. PubMed ID: 14726986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
    Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
    Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response.
    Jannuzzi G; Gatti G; Magni P; Spina E; Pacifici R; Zuccaro P; Torta R; Guarneri L; Perucca E
    Ther Drug Monit; 2002 Oct; 24(5):616-27. PubMed ID: 12352933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients.
    LLerena A; Dorado P; Berecz R; González A; Jesús Norberto M; de la Rubia A; Cáceres M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):25-31. PubMed ID: 12450521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Fluoxetine and Norfluoxetine Pharmacokinetic Profiles Using Physiologically Based Pharmacokinetic Modeling.
    Jeong HC; Chae YJ; Lee S; Kang W; Yun HY; Shin KH
    J Clin Pharmacol; 2021 Nov; 61(11):1505-1513. PubMed ID: 34118174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution and excretion of fluoxetine and norfluoxetine in human milk.
    Kristensen JH; Ilett KF; Hackett LP; Yapp P; Paech M; Begg EJ
    Br J Clin Pharmacol; 1999 Oct; 48(4):521-7. PubMed ID: 10583022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects.
    Liu ZQ; Cheng ZN; Huang SL; Chen XP; Ou-Yang DS; Jiang CH; Zhou HH
    Br J Clin Pharmacol; 2001 Jul; 52(1):96-9. PubMed ID: 11453896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.
    Sager JE; Lutz JD; Foti RS; Davis C; Kunze KL; Isoherranen N
    Clin Pharmacol Ther; 2014 Jun; 95(6):653-62. PubMed ID: 24569517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
    Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers.
    Harvey AT; Preskorn SH
    J Clin Psychopharmacol; 2001 Apr; 21(2):161-6. PubMed ID: 11270912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-)genetic factors.
    Magalhães P; Alves G; Fortuna A; Llerena A; Falcão A;
    Exp Clin Psychopharmacol; 2020 Oct; 28(5):589-600. PubMed ID: 31750687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of selective serotonin reuptake inhibitors.
    Hiemke C; Härtter S
    Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CYP2C19 Variants on Fluoxetine Metabolism in vitro.
    Fang P; He JY; Han AX; Lan T; Dai DP; Cai JP; Hu GX
    Pharmacology; 2017; 100(1-2):91-97. PubMed ID: 28494448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia.
    Stedman CA; Begg EJ; Kennedy MA; Roberts R; Wilkinson TJ
    Hum Psychopharmacol; 2002 Jun; 17(4):187-90. PubMed ID: 12404686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics.
    Piergies AA; Sweet J; Johnson M; Roth-Schechter BF; Allard S
    Int J Clin Pharmacol Ther; 1996 Apr; 34(4):178-83. PubMed ID: 8861737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
    Fjordside L; Jeppesen U; Eap CB; Powell K; Baumann P; Brøsen K
    Pharmacogenetics; 1999 Feb; 9(1):55-60. PubMed ID: 10208643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin.
    Hamelin BA; Turgeon J; Vallée F; Bélanger PM; Paquet F; LeBel M
    Clin Pharmacol Ther; 1996 Nov; 60(5):512-21. PubMed ID: 8941024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration.
    Sawyer EK; Howell LL
    Pharmacology; 2011; 88(1-2):44-9. PubMed ID: 21757974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.